UB Paderborn / Katalog / Suche / in CDI

Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia

Acta psychiatrica Scandinavica, 2014-10, Vol.130 (4), p.290-299

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of primary negative symptoms on functional outcomes in schizophrenia

European psychiatry, 2014-09, Vol.29 (7), p.449-455

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient functioning and health-related quality of life (HRQoL) should be prioritised in the treatment of schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S762-S763

Agid, O

2016

Link zum Volltext

Verfügbarkeit prüfen

Adherence to clozapine vs. other antipsychotics in schizophrenia

Acta psychiatrica Scandinavica, 2020-08, Vol.142 (2), p.87-95

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits

Schizophrenia research, 2011-10, Vol.132 (1), p.24-27

2011

Link zum Volltext

Verfügbarkeit prüfen

Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification

Schizophrenia bulletin, 2013-11, Vol.39 (6), p.1169-1172

2013

Link zum Volltext

Verfügbarkeit prüfen

Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use

Expert opinion on drug safety, 2016-09, Vol.15 (9), p.1193-1203

2016

Link zum Volltext

Verfügbarkeit prüfen

Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia

Schizophrenia research, 2015-08, Vol.166 (1), p.276-282

2015

Link zum Volltext

Verfügbarkeit prüfen

Clozapine administration in clinical practice: once-daily versus divided dosing

Acta psychiatrica Scandinavica, 2016-09, Vol.134 (3), p.234-240

2016

Link zum Volltext

Verfügbarkeit prüfen

C.04.03 Clinical phenotypes of treatment resistance in schizophrenia

European neuropsychopharmacology, 2019, Vol.29, p.S620-S621

Agid, O.

2019

Link zum Volltext

Verfügbarkeit prüfen

C.09.03 - D2 partial agonists: their pharmacology and potential role in schizophrenia

European neuropsychopharmacology, 2017-10, Vol.27, p.S1137-S1138

Agid, O.

2017

Link zum Volltext

Verfügbarkeit prüfen

D 2 partial agonists: their pharmacology and potential role in schizophrenia

European neuropsychopharmacology, 2017-10, Vol.27, p.S1137-S1138

Agid, O.

2017

Link zum Volltext

Verfügbarkeit prüfen

Environment and vulnerability to major psychiatric illness : a case control study of early parental loss in major depression, bipolar disorder and schizophrenia

Molecular psychiatry, 1999-03, Vol.4 (2), p.163-172

1999

Link zum Volltext

Verfügbarkeit prüfen

C.04.06 - Patient functioning and health-related quality of life (HRQoL) should be prioritised in the treatment of schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S762-S763

Agid, O.

2016

Link zum Volltext

Verfügbarkeit prüfen

The different trajectories of antipsychotic response: antipsychotics versus placebo

Psychological medicine, 2011-07, Vol.41 (7), p.1481-1488

2011

Link zum Volltext

Verfügbarkeit prüfen

P.3.b.034 Insight, treatment outcomes and recovery in first-episode schizophrenia

European neuropsychopharmacology, 2013-10, Vol.23, p.S449-S449

2013

Link zum Volltext

Verfügbarkeit prüfen

P.3.d.038 Insight into illness and uncooperativeness in chronic schizophrenia

European neuropsychopharmacology, 2014-10, Vol.24, p.S544-S544

2014

Link zum Volltext

Verfügbarkeit prüfen

P.3.d.064 Antipsychotic re-challenge in previous responders

European neuropsychopharmacology, 2014-10, Vol.24, p.S560-S560

2014

Link zum Volltext

Verfügbarkeit prüfen

The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology

European neuropsychopharmacology, 2016-10, Vol.26, p.S547-S548

2016

Link zum Volltext

Verfügbarkeit prüfen

P.1.j.027 Insight into illness and subjective quality-of-life assessment in chronic schizophrenia

European neuropsychopharmacology, 2013-10, Vol.23, p.S297-S297

2013

Link zum Volltext

Verfügbarkeit prüfen

C.06.02 Can our patients do better? The relationship between motivational deficits and functional outcomes

European neuropsychopharmacology, 2012-10, Vol.22, p.S446-S447

2012

Link zum Volltext

Verfügbarkeit prüfen

Environmental stress and psychiatric illness

Biomedicine & pharmacotherapy, 2000-04, Vol.54 (3), p.135-141

2000

Link zum Volltext

Verfügbarkeit prüfen

P.1.h.006 Study quality and placebo response in randomised controlled trials in schizophrenia conducted 1966–2009

European neuropsychopharmacology, 2011, Vol.21, p.S351-S352

2011

Link zum Volltext

Verfügbarkeit prüfen

S.05.03 The inherent trajectories in antipsychotic response: beyond simple responders and non-responders

European neuropsychopharmacology, 2009, Vol.19, p.S184-S184

2009

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment

The American journal of psychiatry, 2005-05, Vol.162 (5), p.939-946

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia

Impact of primary negative symptoms on functional outcomes in schizophrenia

Patient functioning and health-related quality of life (HRQoL) should be prioritised in the treatment of schizophrenia

Adherence to clozapine vs. other antipsychotics in schizophrenia

Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits

Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification

Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use

Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia

Clozapine administration in clinical practice: once-daily versus divided dosing

C.04.03 Clinical phenotypes of treatment resistance in schizophrenia

C.09.03 - D2 partial agonists: their pharmacology and potential role in schizophrenia

D 2 partial agonists: their pharmacology and potential role in schizophrenia

Environment and vulnerability to major psychiatric illness : a case control study of early parental loss in major depression, bipolar disorder and schizophrenia

C.04.06 - Patient functioning and health-related quality of life (HRQoL) should be prioritised in the treatment of schizophrenia

The different trajectories of antipsychotic response: antipsychotics versus placebo

P.3.b.034 Insight, treatment outcomes and recovery in first-episode schizophrenia

P.3.d.038 Insight into illness and uncooperativeness in chronic schizophrenia

P.3.d.064 Antipsychotic re-challenge in previous responders

The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology

P.1.j.027 Insight into illness and subjective quality-of-life assessment in chronic schizophrenia

C.06.02 Can our patients do better? The relationship between motivational deficits and functional outcomes

Environmental stress and psychiatric illness

P.1.h.006 Study quality and placebo response in randomised controlled trials in schizophrenia conducted 1966–2009

S.05.03 The inherent trajectories in antipsychotic response: beyond simple responders and non-responders

Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment

Suchergebnisse filtern